original ) (raw )BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients
Frank Mugabe
Breast cancer research and treatment, 2018
View PDFchevron_right
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Sarah Asad
npj Breast Cancer
View PDFchevron_right
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making
Gianluca Franceschini
Cancers, 2022
View PDFchevron_right
Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer
DHIRAJ YADAV
Clinical breast cancer, 2017
View PDFchevron_right
Influence of Germline BRCA Genotype on the Survival of Patients with Triple-Negative Breast Cancer
Yanin Chavarri-Guerra
Cancer Research Communications
View PDFchevron_right
Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Bert van Geel
Journal of Clinical Oncology, 2009
View PDFchevron_right
Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers
Anna Sokolenko , Alexandr Ivantsov
Breast Cancer Research and Treatment, 2014
View PDFchevron_right
Data from Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
Silvana Lanzalone
View PDFchevron_right
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
Jelle Wesseling
British Journal of Cancer
View PDFchevron_right
The fate of BRCA1-related germline mutations in triple-negative breast tumors
Drakoulis Yannoukakos
American journal of cancer research, 2017
View PDFchevron_right
BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis
Shafiqul Islam
2012
View PDFchevron_right
Supplementary Data Tables from Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study
Kimberly Jen
2023
View PDFchevron_right
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
Silvana Lanzalone
Clinical Cancer Research, 2022
View PDFchevron_right
Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer
Kristen Shannon
Clinical Cancer Research, 2020
View PDFchevron_right
BRCA1/2 mutations and triple negative breast cancers
Michelle Alabek
Breast disease, 2010
View PDFchevron_right
Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
J. Gronwald
Journal of Clinical Oncology, 2010
View PDFchevron_right
Pathogenic variants inBRCA1/2genes among patientswith triple-negative breast cancer: a case series
Dr Sabas Vieira
Mastology
View PDFchevron_right
The Relationship of Mutation Carriage of BRCA1/2 and Family History in Triple-Negative Breast Cancer: Experience from a Diagnostic Center in Turkey
Olcay Kandemir
The Journal of Breast Health, 2021
View PDFchevron_right
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer
Kirsten Timms
Clinical Cancer …, 2011
View PDFchevron_right
Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study
Orcun Can
European Journal of Breast Health, 2021
View PDFchevron_right
Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline BRCA1/2 Mutation
Jimi Choi
Cancer Research and Treatment
View PDFchevron_right
Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations
Joseph Bui
Radiotherapy and Oncology, 1998
View PDFchevron_right
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study
Evangelia Razis
Clinical Cancer Research, 2021
View PDFchevron_right
Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer
Alois Lang
Journal of Cancer Research and Clinical Oncology, 2015
View PDFchevron_right
Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis
cristina frutuoso
Hereditary Cancer in Clinical Practice
View PDFchevron_right
Clinicopathological characteristics and BRCA1/BRCA2 pathogenic variants of patients with breast cancer
Nazan Eras
Polish Journal of Pathology, 2024
View PDFchevron_right
Case Report: Complete Clinical Response of a Young Patient with a BRCA 2 Positive Metastatic Breast Cancer
Giuseppe Azzarello
Advances in Breast Cancer Research, 2013
View PDFchevron_right
Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations 1 This work was presented at the 21st meeting of the International Association for Breast Cancer Research, 3 July 1996, Paris, France. 1
Joseph Bui
Radiotherapy and Oncology, 1998
View PDFchevron_right
Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Anne-sophie Hamy
Cancers, 2020
View PDFchevron_right
Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort
Keren Levanon
The Breast, 2018
View PDFchevron_right
Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer
Ayala Hubert
Familial Cancer, 2009
View PDFchevron_right
Genomic patterns resembling BRCA1-and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
Jelle Wesseling
View PDFchevron_right